Organogenesis Holdings (Organogenesis Holdings) FCF Margin % : 7.31% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Organogenesis Holdings's Free Cash Flow for the three months ended in Dec. 2023 was $7.3 Mil. Organogenesis Holdings's Revenue for the three months ended in Dec. 2023 was $99.7 Mil. Therefore, Organogenesis Holdings's FCF Margin % for the quarter that ended in Dec. 2023 was 7.31%.

As of today, Organogenesis Holdings's current FCF Yield % is 2.11%.

The historical rank and industry rank for Organogenesis Holdings's FCF Margin % or its related term are showing as below:

ORGO' s FCF Margin % Range Over the Past 10 Years
Min: -32.3 Med: -3.3 Max: 6.58
Current: 1.51

During the past 9 years, the highest FCF Margin % of Organogenesis Holdings was 6.58%. The lowest was -32.30%. And the median was -3.30%.

ORGO's FCF Margin % is ranked better than
56.34% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs ORGO: 1.51

Organogenesis Holdings FCF Margin % Historical Data

The historical data trend for Organogenesis Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organogenesis Holdings FCF Margin % Chart

Organogenesis Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-15.24

-3.61

6.58

-2.00

1.51

Organogenesis Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-2.47	-11.74	0.98	9.91	7.31

Competitive Comparison of Organogenesis Holdings's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organogenesis Holdings's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's FCF Margin % falls into.

Organogenesis Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Organogenesis Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	6.553	/	433.14
	=	1.51 %

Organogenesis Holdings's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	7.289	/	99.651
	=	7.31 %

Organogenesis Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Organogenesis Holdings (Organogenesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

2PQ:Germany

Address

85 Dan Road, Canton, MA, USA, 02021

Website

https://www.organogenesis.com

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.

Executives

Albert Erani	10 percent owner	150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz	10 percent owner
Arthur S Leibowitz	director	139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Michael Joseph Driscoll	director	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney	director, officer: President and CEO	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gilberto Quintero	director	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin	director	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo	officer: VP Health Policy & Contracting	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin	director	7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco	officer: Chief Financial Officer	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc	10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu	director	C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf	director, 10 percent owner
Alan A. Ades	director, 10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016	10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021